DelveInsight’s, “Alcohol Use Disorder Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Alcohol Use Disorder pipeline landscape. It covers the Alcohol Use Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alcohol Use Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Alcohol Use Disorder Pipeline. Dive into DelveInsight’s comprehensive report today! @ Alcohol Use Disorder Pipeline Outlook

Key Takeaways from the Alcohol Use Disorder Pipeline Report

• In June 2025, Eli Lilly and Company announced a study to evaluate mazdutide in participants with alcohol use disorder (AUD).
• In June 2025, Altimmune Inc. announced a phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight.
• DelveInsight’s Alcohol Use Disorder Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Alcohol Use Disorder treatment.
• The leading Alcohol Use Disorder Companies such as Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, Imbrium Therapeutics and others.
• Promising Alcohol Use Disorder Pipeline Therapies such as Sunobinop, ASP8062, Phytocannabinoid cannabidiol (CBD), Mazdutide, BPL-003, Psilocybin, Ibudilast, GET73 and others.

Stay ahead with the most recent pipeline outlook for Alcohol Use Disorder. Get insights into clinical trials, emerging therapies, and leading companies with Alcohol Use Disorder @ Alcohol Use Disorder Treatment Drugs

Alcohol Use Disorder Emerging Drugs Profile

• AD04: Adial Pharmaceuticals

AD04, developed by Adial Pharmaceuticals, is a genetically targeted therapeutic agent designed to treat Alcohol Use Disorder (AUD). It works by modulating specific neurotransmitter pathways that are implicated in the brain’s reward and reinforcement circuits related to alcohol consumption. The drug is being developed for patients with particular genetic markers, identified through a proprietary companion diagnostic genetic test, and has shown promise in reducing heavy drinking days in a subgroup of patients during a Phase III clinical trial. AD04’s mechanism of action is believed to involve balancing the activity of the serotonergic and dopaminergic systems, potentially reducing alcohol cravings and consumption.

• Sunobinop: Imbrium Therapeutics

Sunobinop is an investigational, novel and potential first-in-class oral compound designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), a protein that is widely expressed in the central and peripheral nervous system and involved in a range of biological functions. Currently, the drug is in Phase II stage of its clinical trial for the treatment of alcohol use disorder.

• BICX104: BiocorRx Pharmaceuticals

BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder (OUD) being developed to improve patient compliance to naltrexone therapy compared to other marketed treatments. In Phase I, an open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the PK and safety of BICX104 and the once-a-month intramuscular naltrexone injection (Vivitrol), BICX104 was well tolerated with no serious adverse events and achieved 84 days of therapeutic naltrexone plasma concentrations. BICX104 is being developed under BioCorRx Pharmaceuticals Inc., the Company’s majority-owned clinical-stage pharmaceutical subsidiary. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Alcohol Use Disorder.

The Alcohol Use Disorder Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Alcohol Use Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alcohol Use Disorder Treatment.
• Alcohol Use Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Alcohol Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alcohol Use Disorder market

Explore groundbreaking therapies and clinical trials in the Alcohol Use Disorder Pipeline. Access DelveInsight’s detailed report now! @ New Alcohol Use Disorder Drugs

Alcohol Use Disorder Companies

Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, Imbrium Therapeutics and others.

Alcohol Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Alcohol Use Disorder Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Alcohol Use Disorder Treatment. Learn about new drugs, Alcohol Use Disorder Pipeline developments, and key companies with DelveInsight’s expert analysis @ Alcohol Use Disorder Market Drivers and Barriers

Scope of the Alcohol Use Disorder Pipeline Report

• Coverage- Global
• Alcohol Use Disorder Companies- Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, Imbrium Therapeutics and others.
• Alcohol Use Disorder Pipeline Therapies- Sunobinop, ASP8062, Phytocannabinoid cannabidiol (CBD), Mazdutide, BPL-003, Psilocybin, Ibudilast, GET73 and others.
• Alcohol Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Alcohol Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Alcohol Use Disorder Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Alcohol Use Disorder Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Alcohol Use Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Alcohol Use Disorder– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. AD04: Adial Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Sunobinop: Imbrium Therapeutics
12. Early Stage Products (Phase I)
13. BICX104: BiocorRx Pharmaceuticals
14. Preclinical and Discovery Stage Products
15. Drug name: Company name
16. Inactive Products
17. Alcohol Use Disorder Key Companies
18. Alcohol Use Disorder Key Products
19. Alcohol Use Disorder- Unmet Needs
20. Alcohol Use Disorder- Market Drivers and Barriers
21. Alcohol Use Disorder- Future Perspectives and Conclusion
22. Alcohol Use Disorder Analyst Views
23. Alcohol Use Disorder Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/alcohol-use-disorder-pipeline-insight